Celgene

Part of Bristol Myers Squibb

CompanyUnited StatesFounded 1986

RORWikidata

Celgene develops 4 assets, the furthest approved (lisocabtagene maraleucel in follicular lymphoma). Mostly protein or enzyme and cell therapy acting on CD19, TGFB2 and TGFB1; based in the United States, founded in 1986.

4
Assets
Furthest stage
Approved
228
Trials
31
Signals

Pipeline

4
  • lisocabtagene maraleucel

    Engineered CAR T cells recognize CD19 and kill CD19-expressing malignant B cells.

    Approved, Cell therapy, CD19, follicular lymphoma, diffuse large B-cell lymphoma

  • Luspatercept

    Traps select TGF-beta superfamily ligands, reducing SMAD2/3 signaling to promote late-stage red blood cell maturation.

    Approved, Protein or enzyme, TGFB2, TGFB1, anemia, beta thalassemia

  • sotatercept

    Traps activin-family ligands to rebalance vascular signaling and reduce pulmonary vascular remodeling.

    Approved, Protein or enzyme, INHBA, pulmonary arterial hypertension, pulmonary hypertension (Phase 3)

1 more asset

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms7
  • Trials731
  • Signals20
  • Similar companies6

Papers

Intelligence